Sol Gel Technologies LtdNASDAQ:SLGL
- LAST PRICE0.9001
- TODAY'S CHANGE (%)0.0432 (5.0414%)
- Bid / Lots0.9000/ 5
- Ask / Lots0.9448/ 6
- Open / Previous Close0.8569 / 0.8569
- Day Range
- 52 Week Range
- Volume1,828
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SLGL |
|---|---|---|
| 09:32 ET | 100 | 0.8569 |
| 10:50 ET | 500 | 0.95 |
| 12:52 ET | 100 | 0.9001 |
Apr 1, 2024
Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve(R) Cream, from 7:00AM ET on Monday Apr 01, 2024 by Dow Jones
7:00AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sol Gel Technologies Ltd | 23.9M | -0.9x | --- |
OncoCyte Corp | 21.4M | -0.9x | --- |
Lumos Pharma Inc | 20.5M | -0.6x | --- |
Oncternal Therapeutics Inc | 26.5M | -0.6x | --- |
AIM ImmunoTech Inc | 23.7M | -0.8x | --- |
Iterum Therapeutics PLC | 24.0M | -0.5x | --- |
Company Information
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Contact Information
- Headquarters
- Golda Meir 7NESS-ZIONA, Israel 7403650
- Phone
- ---
- Fax
- ---
Executives
- Executive Chairman of the Board
- Moshe Arkin
- Chief Executive Officer, Co-Founder, Director
- Alon Seri-Levy
- Chief Financial Officer
- Gilad Mamlok
- Vice President - Operations
- Itzik Yosef
- Vice President - Quality
- Nissim Bilman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $23.9M |
|---|---|
Revenue (TTM) | $1.6M |
Shares Outstanding | 27.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.34 |
EPS | $-1.02 |
Book Value | $1.39 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 15.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,885.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
